Member Info for HotblackDesiato

Thanks Nav.

I don't have access to L2 but would that show any unfilled large orders?

An interesting read on manipulation - https://discoveryalert.com.au/automated-trading-dark-side-2025-manipulation/

Plus GSK's CEO was at Sierra so he'll know all about 737.

I see GSK are running trials on their own ovarian cancer drug - https://www.theguardian.com/business/2026/apr/12/gsk-promising-early-results-ovarian-womb-cancer-drug-trial

However, their drug is administered every three weeks via intravenous infusion. On the other hand, a quick search shows you can get hydroxyurea capsules for about 20 cents each. You can even find discount coupons for it.

I'm not suggesting treatment is a clear-cut 'this' is better than 'that' but if 737+hydroxyurea (both taken orally!) could be proven to be effective in human trials then what would the patient (and medical insurance provider) prefer?

Time for the BoD to get their skates on and push for a deal.

For those wondering why B&I transactions are no longer being reported in the list of trades -

"Bed & ISA transactions are considered private transactions. They are not part of the public trading market, which means they do not get recorded in the same way as regular trades on the LSE. Since these transactions involve selling and repurchasing the same investments, they do not affect the market's trading records or prices. This helps maintain market stability and prevents unnecessary fluctuations that could arise from large buy or sell orders."

Regards all.

No problem, AOTD. If I can share data that supports my investment with other investors (and the company!), it can only be a positive. Even if you don't understand the science, a paper linked to any of our compounds appearing in a noted journal must give even the most jaded investor some hope that all is not lost. Despite the setbacks we've experienced over the years I think we'll see some reward in the year to come....otherwise I'm stuffed.

I think 737 has appeared to have 'sat around for some time now' as you put it is simply down to being in the wrong place at the wrong time. Sierra created a number of patent applications relating to 737 and their head honcho, Luke Miels (now CEO at GSK), seemed rather positive about 737. When GSK came along they only wanted one thing and all other compounds licensed to Sierra reverted back whence they came. Tough luck. When 737 was licensed to the anonymous US start-up business, I'm guessing they couldn't raise funds to run the proposed trial (despite having the IND registered with the FDA) because they were possibly viewed simply as a minnow and asking for too much money without perhaps having a track record to rely on.

SP has said they are still talking with a number of interested parties and hoped that would translate into something more concrete in the near to mid-term. We shall see. Any income from a 737 deal would put us in a very good place when it comes to attracting partners for 1801 (assuming the tox study goes without a hitch).

Regards.

737 + low-dose hydroxyurea can also work against melanomas: https://www.mdpi.com/2072-6694/17/11/1817

Interesting that the above research and the latest ovarian cancer study were both carried out in Australia by some of the same staff. It's like a giant game of join the dots...

Hi Stevej - got a reply from IR to say they'd also add it to the publications page of the website.

Glad to see my digging is worthwhile!

Tell 'em to get stuffed at that price. We should be closer to 50p by now.

I've pinged off an e-mail to IR@SAR as it might be worth putting a link on the Publications page. Nature & The British Journal of Cancer don't publish any old tosh so I guess it's another resource if we get to negotiations with big pharma.

Published yesterday https://www.nature.com/articles/s41416-026-03416-y

"Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer"

The CHK1 inhibitor used was 737 -

"Background: High-grade serous ovarian cancer (HGSOC) is characterized by elevated replication stress and an immunosuppressive microenvironment. A synergistic combination of checkpoint kinase 1 inhibitor (CHK1i) with low-dose hydroxyurea (LDHU) promotes a unique ATR-independent moderate replication stress response with potent anti-tumour effects. The ability of this approach to reprogram the tumour immune microenvironment (TIME) to overcome the immunosuppression and promote an anti-tumour immune response in HGSOC is the focus of this study."

"In conclusion, synergistic CHK1i+LDHU combination therapy represents a promising strategy for treating HGSOC by directly killing tumour cells and importantly, reprogramming the immune microenvironment to promote an effective anti-tumour immune response in vivo. By including primary tumour cells derived from patient ascites alongside a diverse panel of established human ovarian cancer cell lines, this study provides strong evidence that the efficacy of CHK1i+LDHU extends to clinically relevant, heterogeneous tumour contexts. The high sensitivity in diverse HGSOC models, even in models derived from chemo-resistant patients suggests that the CHK1i combination could be an effective option for patients who have exhausted standard treatment options."

Good to know our patent goes on 'til 2041. If I picked SP up correctly at the IM event, whist they're not in negotiations just yet, he gave the impression it shouldn't be too long until talks with interested parties get serious.

Regards.

I think I worked it out as £33.

Hi Bailiff - my own Halifax B&I went through this morning but isn't even showing on the proper LSE transaction site. Mysteries of the universe. I only had 36375 shares in my non-ISA account and if my calcs are right the sell part of that transaction was about 14.9p and I 'lost' 330 shares. Hopefully there will be news on a 737 deal soon to bolster the sp. Still underwater but I'm used to it now!

Any idea why some trades aren't showing up on here? My buy was first trade of the day but no sign of it in the list though it appears on the 'official' stock exchange website's list of trades. Meh....

Hi Bailiff - just added another £5k at 15.2p to the pot and arranged my Bed & ISA to put all my shares out of the hands of the Chancellor.

Onwards!

Hi PCS - anything is possible in the pharma world but if someone set out to deliberately torpedo 737 via a rigged trial, they'd be found out when they announced results and published their perhaps 'questionable' methodology. Look at last year's 1801 tox trial - if the compound isn't the cause of failure, all eyes look to the staff operating the trial.

Hi PCS, there are plenty of suppliers offering 737 for sale but they don't give much info beyond a brief description & storage details. Looks like BenchChem can also arrange synthesis and chemical analysis. They provide similar data & collated (pre)clinical research results for other compounds too.

Hi Mayhem, as far as I'm aware researchers and companies involved in drug development are allowed to use a compound for preclinical trials without the license holder's permission. However if someone wanted to do a clinical study in people then they would need a license from SAR - just because you bought a book doesn't mean you have full commercial rights to turn it into a film! The various companies that can supply quantities of 737 all state "For research use only. Not for human or veterinary use." I presume if you tried to order some you'd have to provide evidence that you're a research establishment or part of a university etc. and not just a keen amateur willing to give things a bash.

One benefit of researchers being allowed to use a new compound is that the license owner can effectively get free data on their drug in areas they may not have considered - ages ago I unearthed a trial in China where the researchers used 737 in combination with ultrasound to target clinical models of breast cancer. The slight drawback there is hoping the license holder becomes aware of such trials either through their own due diligence or peeps like me and C79 spotting and reporting published results.

Regards.

Just a brief update - SP replied to my e-mail re BenchChem's entry for 737, "I'll ask John to take a look to see if there is any reason why not to draw attention to it."

JR can thank me later for the extra homework!

Hi Bailiff - wasn't there a poster last year (I forget who) who said they'd be selling all their SAR shares around April '26 no matter what?